191 related articles for article (PubMed ID: 29982521)
1. Can public financing of the private sector defeat antimicrobial resistance?
James JE
J Public Health (Oxf); 2019 Jun; 41(2):422-426. PubMed ID: 29982521
[TBL] [Abstract][Full Text] [Related]
2. Is the GAIN Act a turning point in new antibiotic discovery?
Brown ED
Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
[TBL] [Abstract][Full Text] [Related]
3. Bailing out.
Petsko GA
Genome Biol; 2011 Oct; 12(10):131. PubMed ID: 22035635
[No Abstract] [Full Text] [Related]
4. Out-of-pocket health expenditures and antimicrobial resistance in low-income and middle-income countries: an economic analysis.
Alsan M; Schoemaker L; Eggleston K; Kammili N; Kolli P; Bhattacharya J
Lancet Infect Dis; 2015 Oct; 15(10):1203-1210. PubMed ID: 26164481
[TBL] [Abstract][Full Text] [Related]
5. The innovative medicines initiative: a European response to the innovation challenge.
Goldman M
Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
[TBL] [Abstract][Full Text] [Related]
6. Drug development for neglected diseases: a deficient market and a public-health policy failure.
Trouiller P; Olliaro P; Torreele E; Orbinski J; Laing R; Ford N
Lancet; 2002 Jun; 359(9324):2188-94. PubMed ID: 12090998
[TBL] [Abstract][Full Text] [Related]
7. The public economics of tuberculosis control.
Jack W
Health Policy; 2001 Aug; 57(2):79-96. PubMed ID: 11395176
[TBL] [Abstract][Full Text] [Related]
8. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
[TBL] [Abstract][Full Text] [Related]
9. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
Outterson K; McDonnell A
Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
[TBL] [Abstract][Full Text] [Related]
10. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
11. Global access to existing and future antimicrobials and diagnostics: antimicrobial subscription and pooled procurement.
Berman D; Chandy SJ; Cansdell O; Moodley K; Veeraraghavan B; Essack SY
Lancet Glob Health; 2022 Feb; 10(2):e293-e297. PubMed ID: 34914900
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic research and development: business as usual?
Harbarth S; Theuretzbacher U; Hackett J;
J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
[TBL] [Abstract][Full Text] [Related]
13. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
[TBL] [Abstract][Full Text] [Related]
14. Australia's 'free-ride' in pharmaceuticals: can it last?
Kemp R
Aust Health Rev; 1996; 19(1):81-94. PubMed ID: 10157539
[TBL] [Abstract][Full Text] [Related]
15. Eurofile. Private-public drive to cut delays in drug development.
Mundell I
Eur J Cancer; 2008 Jan; 44(2):169. PubMed ID: 18335586
[No Abstract] [Full Text] [Related]
16. Private sector contributions to pharmaceutical science: thirty-five summary case histories.
Zycher B; DiMasi JA; Milne CP
Am J Ther; 2010; 17(1):101-20. PubMed ID: 20027102
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceuticals imports in Tanzania: Overview of private sector market size, share, growth and projected trends to 2021.
Wande DP; Sangeda RZ; Tibalinda P; Mutta IK; Mkumbwa S; Bitegeko A; Kaale E
PLoS One; 2019; 14(8):e0220701. PubMed ID: 31404109
[TBL] [Abstract][Full Text] [Related]
18. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
Simpkin VL; Renwick MJ; Kelly R; Mossialos E
J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
[TBL] [Abstract][Full Text] [Related]
19. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
Matheny J; Smith B; Courtney B; Mair M
Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
[No Abstract] [Full Text] [Related]
20. [Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali].
Maïga D; Maïga S; Maïga MD
Med Trop (Mars); 2010 Apr; 70(2):184-8. PubMed ID: 20486360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
